Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

594
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
594
T Cell Types and Functions01:24

T Cell Types and Functions

3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Types of Signaling Molecules01:32

Types of Signaling Molecules

14.1K
In multicellular organisms, many molecules transmit signals between cells to pass information. These signals vary in complexity and include small peptides, nucleotides, steroids, fatty acid derivatives, and dissolved gases such as nitric oxide. Some signaling molecules diffuse through the plasma membrane to act locally between neighboring cells or travel long distances. Others remain attached to the cell surface, transmitting information to other cells only when they make contact. In some...
14.1K
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

7.3K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.

Journal of psoriasis and psoriatic arthritis·2024
Same author

Wolf's isotopic response of lichen planus following contact dermatitis.

JAAD case reports·2022
Same author

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.

Advances in therapy·2022
Same author

Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).

Journal of drugs in dermatology : JDD·2021
Same author

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.

Drug safety·2021
Same author

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2021
Same journal

Systemic therapy for advanced cutaneous squamous cell carcinoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Atypical Fibroxanthoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Introduction, High-Risk Skin Cancer.

Seminars in cutaneous medicine and surgery·2019
Same journal

Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care.

Seminars in cutaneous medicine and surgery·2019
Same journal

MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research.

Seminars in cutaneous medicine and surgery·2019
Same journal

Digital imaging applications and informatics in dermatology.

Seminars in cutaneous medicine and surgery·2019
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Small Molecules for Psoriasis.

Craig L Leonardi1

  • 1Clinical Professor of Dermatology Saint Louis University Central Dermatology St Louis, Missouri.

Seminars in Cutaneous Medicine and Surgery
|August 16, 2016
PubMed
Summary
This summary is machine-generated.

Acitretin and tofacitinib are oral psoriasis treatments. Both are effective for specific patients but carry significant safety risks.

Keywords:
Acitretinpsoriasispustular psoriasistofacitinibtoxicity

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

993
SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments
06:34

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

648

Related Experiment Videos

Last Updated: Mar 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

993
SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments
06:34

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

648

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Acitretin is an established oral non-immunosuppressive therapy for psoriasis.
  • Tofacitinib is an oral Janus kinase inhibitor investigated for psoriasis treatment.

Purpose of the Study:

  • To compare the efficacy and safety profiles of acitretin and tofacitinib in psoriasis management.
  • To evaluate the suitability of each medication for different patient profiles and clinical scenarios.

Main Methods:

  • Review of existing clinical trial data and pharmacological studies on acitretin and tofacitinib.
  • Analysis of efficacy endpoints and safety risk profiles for both medications.

Main Results:

  • Both acitretin and tofacitinib demonstrate efficacy in treating psoriasis.
  • Each medication presents distinct efficacy in specific patient populations and treatment settings.
  • Substantial safety risks are associated with both acitretin and tofacitinib therapies.

Conclusions:

  • Acitretin and tofacitinib represent viable, yet risk-associated, oral treatment options for psoriasis.
  • Treatment selection requires careful consideration of individual patient factors and risk tolerance.
  • Further research may be needed to optimize the use of these agents and mitigate their adverse effects.